维利西呱是哪一类药,效果如何？

Heart failure (HF) is caused by any structural or functional abnormality of the heart that results in an impairment of the ability of the ventricles to fill or eject blood - a group of complex clinical syndromes called HF. Moreover, heart failure is a serious and terminal stage of various heart diseases with a high incidence rate. It has become the most important cardiovascular disease in the 21st century. Some studies estimate that the prevalence of heart failure in China will increase by 44% in 2035. Although traditional drugs based on inhibiting renin-angiotensin-aldosterone and the sympathetic nervous system have delayed the progression of heart failure and improved clinical symptoms, their morbidity and mortality are still increasing globally. In order to further improve the prognosis of patients with heart failure, the development of new drugs is particularly important. (Vericiguat) is a new oral, soluble guanylyl cyclase agonist that was approved by the FDA in January 2021 for the treatment of cardiac dysfunction. So, what kind of drug is Vericiguat and how effective is it?

What kind of drug is Vericiguat?

Vericiguat is a new type of oral, soluble guanylyl cyclase agonist. Its mechanism of action is mainly to directly stimulate soluble guanylyl cyclase through a binding site unrelated to nitric oxide, and stabilize the combination of nitric oxide and the binding site, making sGC sensitive to endogenous nitric oxide. By enhancing the L-ARG-NO-sGC-cGMP signaling pathway, it improves myocardial and vascular function, prevents or even reverses left ventricular hypertrophy and fibrosis, slows down ventricular remodeling, and reduces ventricular afterload through systemic and pulmonary vasodilation, thereby exerting a therapeutic effect on heart failure through the above mechanisms.

How effective is Vericiguat?

The approval was supported by results from a Phase 3 clinical trial of a drug called vericiguat. This trial is specifically for patients with heart failure. Data from veliciguat has been published in the New England Journal of Medicine. The results at a median follow-up period of 10.8 months showed that the velicigat treatment group reduced the risk of the composite end point of hospitalization for heart failure and death from cardiovascular causes compared with the placebo group (35.5% vs 38.5%, HR=0.90, P=0.02). The data proves that Veliciguat can fully exert its efficacy while ensuring safety.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: